SV2006002258A - Inmunoterapia de trastornos autoinmunes - Google Patents

Inmunoterapia de trastornos autoinmunes

Info

Publication number
SV2006002258A
SV2006002258A SV2005002258A SV2005002258A SV2006002258A SV 2006002258 A SV2006002258 A SV 2006002258A SV 2005002258 A SV2005002258 A SV 2005002258A SV 2005002258 A SV2005002258 A SV 2005002258A SV 2006002258 A SV2006002258 A SV 2006002258A
Authority
SV
El Salvador
Prior art keywords
agents
cell
auto
immunotherapy
diseases
Prior art date
Application number
SV2005002258A
Other languages
English (en)
Inventor
Anand Iyer
Kyriaki Dunussi Joannopoulos
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2006002258A publication Critical patent/SV2006002258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES Y MÉTODOS PARA TRATAR ENFERMEDADES AUTO INMUNES. EN PARTICULAR, SE DESCRIBE EL USO DE AGENTES DE EVACUACIÓN DE LA CÉLULA B Y FUSIONES DE UNA DROGA CITOTÓXICA/AGENTES DE EVACUACIÓN DE LA CÉLULA B CON UNA DROGA DE CARGA SIGNIFICATIVAMENTE MÁS ALTO QUE EN PROCEDIMIENTO REPORTADOS ANTERIORMENTE Y CON AGREGADO MENOR Y UNA FRACCIÓN DE FUSIÓN BAJA (LCF) EN EL TRATAMIENTO DE ENFERMEDADES AUTO INMUNES. TAMBIÉN SE DESCRIBEN TERAPIAS DE COMBINACIÓN Y COMPOSICIONES PARA TRATAR ENFERMEDADES AUTO INMUNES, INCLUYENDO AGENTES DE EVACUACIÓN DE LA CÉLULA B, FUSIONES Y/O AGENTES ANTI-CITOKINES.
SV2005002258A 2004-10-08 2005-10-07 Inmunoterapia de trastornos autoinmunes SV2006002258A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61664704P 2004-10-08 2004-10-08
US68600105P 2005-06-01 2005-06-01

Publications (1)

Publication Number Publication Date
SV2006002258A true SV2006002258A (es) 2006-09-19

Family

ID=36148997

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002258A SV2006002258A (es) 2004-10-08 2005-10-07 Inmunoterapia de trastornos autoinmunes

Country Status (13)

Country Link
US (2) US20070264257A1 (es)
EP (1) EP1796735A4 (es)
JP (1) JP2008515926A (es)
AR (1) AR052774A1 (es)
AU (1) AU2005295041A1 (es)
BR (1) BRPI0516531A (es)
CA (1) CA2582919A1 (es)
GT (1) GT200500283A (es)
MX (1) MX2007004049A (es)
PE (1) PE20060972A1 (es)
SV (1) SV2006002258A (es)
TW (1) TW200630106A (es)
WO (1) WO2006042240A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP2213683B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant Fc regions
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US8097703B2 (en) * 2005-06-20 2012-01-17 Medarex, Inc. CD19 antibodies and their uses
EP2377554A1 (en) * 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
EP1928503B1 (en) 2005-08-24 2012-10-03 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
EP2447282B1 (en) 2006-05-30 2016-01-27 Genentech, Inc. Anti-CD22 Antibodies, their Immunoconjugates and uses thereof
JP2008105953A (ja) * 2006-10-23 2008-05-08 Kyoto Sangyo Univ Ｂ細胞傷害抑制剤
DK2465541T3 (en) 2007-05-22 2018-09-17 Wyeth Llc improved methods for producing hydrazides
JP5719591B2 (ja) * 2007-06-08 2015-05-20 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． 抗ｔｎｆ応答性または非応答性を予測するためのバイオマーカー
MX364200B (es) 2008-04-09 2019-04-16 Genentech Inc Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
WO2010011697A1 (en) * 2008-07-21 2010-01-28 Immunomedics Inc. Structural variants of antibodies for improved therapeutic characteristics
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
PL2437790T3 (pl) 2009-06-03 2019-09-30 Immunogen, Inc. Sposoby sprzęgania
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
JP4495776B1 (ja) * 2009-07-30 2010-07-07 日本製薬株式会社 融合蛋白質
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
KR20220123130A (ko) 2011-03-29 2022-09-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
EA201790757A1 (ru) * 2011-09-22 2017-07-31 Эмджен Инк. Связывающие антиген cd27l белки
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
JP6636920B2 (ja) 2013-07-16 2020-01-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びｔｉｇｉｔ阻害剤を使用するがんの治療方法
WO2016081836A1 (en) * 2014-11-21 2016-05-26 Ehrenpreis Eli D Combination therapy for administration of monoclonal antibodies
EP3344658B1 (en) 2015-09-02 2022-05-11 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
CN113912724A (zh) 2015-09-25 2022-01-11 豪夫迈·罗氏有限公司 抗tigit抗体和使用方法
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
CN115054587B (zh) * 2022-05-12 2023-11-21 山东大学 一种胎盘靶向纳米药物的制备及在妊娠合并自身免疫性疾病治疗中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331644T3 (es) * 1999-06-09 2010-01-12 Immunomedics, Inc. Inmunoterapia de trastornos autoinmunes usando anticuerpos cuya diana son celulas b.
US20040001828A1 (en) * 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
EP2301966A1 (en) * 2002-12-16 2011-03-30 Genentech, Inc. Immunoglobulin variants and uses thereof
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins

Also Published As

Publication number Publication date
EP1796735A4 (en) 2007-12-12
MX2007004049A (es) 2007-05-24
US20110027273A1 (en) 2011-02-03
EP1796735A2 (en) 2007-06-20
WO2006042240A2 (en) 2006-04-20
AU2005295041A1 (en) 2006-04-20
AR052774A1 (es) 2007-04-04
CA2582919A1 (en) 2006-04-20
JP2008515926A (ja) 2008-05-15
WO2006042240A3 (en) 2006-09-21
GT200500283A (es) 2006-05-08
TW200630106A (en) 2006-09-01
BRPI0516531A (pt) 2008-09-09
PE20060972A1 (es) 2006-12-03
US20070264257A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
SV2006002258A (es) Inmunoterapia de trastornos autoinmunes
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
UY28287A1 (es) Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
TW200602078A (en) Uses of anti-CTLA-4 antibodies
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
DOP2006000013A (es) Dosis de anticuerpos en el tratamiento de enfermedades asociadas a las celulas b
UY27720A1 (es) Aroilpiridinonas monocíclicas,
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
GT200600046A (es) Terapia de combinacion
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
AR034746A1 (es) Combinaciones para el tratamiento de trastornos inflamatorios
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
AR061122A1 (es) Regimen de cladribina para tratar la escleorosis multiple
ATE284698T1 (de) Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten
CL2008001620A1 (es) Induccion de fenotipo tolerogenico en celulas dendriticas maduras
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
CL2008001104A1 (es) Compuestos derivados de [1,2,3]triazolo[4,5-b]piridin-carboxamidas y [1,2,3]triazolo[4,5-d]pirimidin-carboxamidas, inhibidores de mgl y faah; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de delolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metaloico, dispipidemia, entre otros.
CR8574A (es) Compuestos silinano como inhibidores de cisteina proteasa
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
UA94213C2 (ru) Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
WO2007136910A3 (en) Eimmunotherapy for immune suppressed patients
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
ECSP10010716A (es) Combinaciones farmaceuticas.

Legal Events

Date Code Title Description
FD Lapse